As a likely consequence of global warming, ticks areas are expanding in Europe. A study used artificial intelligence to predict the location of tick areas, evaluate their expansion and locate ticks carrying specific bacteria.
A 25-year-old male with no known immunodeficiency was infected with SARS-CoV-2 in March and was reinfected in May 2020. Genomic sequencing provides strong evidence that this was reinfection.
New research highlights the extent of the new coronavirus transmission by aerosol. Droplets smaller than 100 μm containing viral particles can remain suspended in the air for a long time and be inhaled.
A review on the effectiveness of general screening for SARS-CoV-2, compared to absence of screening and accuracy of general screening in people apparently not affected by COVID-19 were published.
The media in German-speaking Switzerland have enthusiastically reported on a study suggesting that Echinaforce® could be effective against SARS-CoV-2, raising doubts in the scientific community.
Dr. Paul Garassus, president of the UEHP, discusses the role of the private health system in the current COVID-19 pandemic and the regional space for improvement in this contingency.
The risk of falling during stroke rehabilitation is an important issue but with little available data. A recent study shows unexpected results on mobilization in the sub-acute phase after strokes.
Myositides can occur idiopathically or - much less well known - in combination with medication. If left untreated, severe, irreversible or even fatal progressions are possible.
Before Sir Alexander Fleming discovered penicillin in 1928, syphilis treatments were nightmarish and included mercury vapors or getting injected with a potentially fatal disease.
Studies show a causal relationship between different risk factors and microangiopathies, one of the main causes of vascular dementia. They also shed light on the effectiveness of therapeutic approaches.
A study saw a 13% rate of serious neurological complications in hospitalized COVID-19 patients. Mortality rate was almost 40% higher than in hospitalized COVID-19 patients without neurological complications.
October 29 is World Stroke Day and stroke therapy is a core topic at the 93rd DGN Congress. Reducing stroke mortality will depend on treating more patients, faster, specially within the 'golden hour' after stroke.
Most brain changes after a COVID-19 infection are not caused by the virus, but by the body's immune response. The findings are from a study that examined 43 deceased people infected with SARS CoV-2.
Only riluzole can slow down ALS progression, and multimodal supportive therapy is the option left. A phase-II trial showed that oral administration of sodium phenylbutyrate and taurursodiol could delay progression.
A major meta-analysis confirms the advantages of catheter intervention for more severe and moderate strokes. This therapeutic option must also be made available in rural regions.
The device will be called VIKI (VIrus KIller) and can be used in schools, public offices, hospitals, dental surgeries and businesses. It aims to remove over 99.9% of bioaerosol particles.
An algorithm detects signs of osteoarthritis on an MRI scan before the first symptoms appear. With artificial intelligence, treatments could rely on drugs rather than surgery.
The latest findings in dermatological pathology - from newly discovered diseases to the background of "COVID toes" are briefly and concisely summarised.
OLLs are often triggered by medication or are a concomitant symptom of underlying inflammatory diseases, and are very similar to oral lichen planus. Differentiation and finding triggering factors is challenging.
Based on the immune cells involved in the inflammatory reaction, phenotypic differences occur. For optimal therapy, factors must be taken into account to treat the diseases’ subgroups